Results 61 to 70 of about 17,845 (225)

A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda

HIV Medicine
Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dolutegravir‐based regimens to ...
E. L. Odongpiny, M. Nicol, Elizabeth B. Katana, Joseph Owori, Allan Buzibye, Kay Sedan, M. Kesby, Matthew Holden, Noela Owarwo, David Meya, B. Castelnuovo, D. Sloan, C. Sekaggya   +12 more
semanticscholar   +1 more source

IMPLEMENTATION AND OUTCOMES OF DOLUTEGRAVIR-BASED FIRST-LINE ANTIRETROVIRAL THERAPY FOR PEOPLE WITH HIV IN SOUTH AFRICA: A RETROSPECTIVE COHORT STUDY

The Lancet HIV, 2023
Background There is little data evaluating uptake of first-line dolutegravir among men and women living with HIV in low- and middle-income countries, and subsequent clinical outcomes in non-trial settings.
J. Dorward, Yukteshwar Sookrajh, Thokozani Khubone, J. van der Molen, Riona Govender, S. Phakathi, Lara Lewis, C. Bottomley, Munthra Maraj, R. Lessells, K. Naidoo, Christopher C. Butler, Rose van Heerden, N. Garrett   +13 more
semanticscholar   +1 more source

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS

, 2015
Huda Taha,1 Archik Das,2 Satyajit Das1,3 1Integrated Sexual Health Service Coventry and Warwickshire Partnership NHS Trust, Coventry, 2School of Medicine, Birmingham University, Birmingham, 3Coventry University, Coventry, UK Abstract: Dolutegravir (DTG)
Taha H, Satyajit Das, Das, A., Taha, H., Das, S., Huda Taha, Das S, Archik Das, Das A   +8 more
core   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Comparative effectiveness of bictegravir versus dolutegravir, raltegravir, and efavirenz-based antiretroviral therapy among treatment-naïve individuals with HIV.

European journal of internal medicine
OBJECTIVE Bictegravir or dolutegravir based antiretroviral therapy are first-line HIV treatments. However, no trial has recruited enough participants to estimate the most effective treatment, and there is little evidence on the comparative effectiveness ...
I. Núñez, Y. Caro-Vega, C. MacDonald, J. Mosqueda, Alicia Piñeirúa-Menéndez, Anthony A. Matthews   +5 more
semanticscholar   +1 more source

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.

New England Journal of Medicine, 2021
BACKGROUND The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this
Nicholas I. Paton, J. Musaazi, C. Kityo, S. Walimbwa, A. Hoppe, Apolo Balyegisawa, A. Kaimal, G. Mirembe, Phionah Tukamushabe, Gilbert Ategeka, J. Hakim, H. Mugerwa, A. Siika, Jesca Asienzo, B. Castelnuovo, A. Kiragga, A. Kambugu   +16 more
semanticscholar   +1 more source

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy

International Journal of Infectious Diseases, 2021
Objectives: The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART).
Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Aristine Cheng, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung   +9 more
doaj   +1 more source

PREPARATION AND EVALUATION OF DOLUTEGRAVIR SOLID DISPERSIONS

, 2021
Objective: The current work mainly focuses on solubility enhancement of dolutegravir which is a BCS (Biopharmaceutical Classification System) class-II drug using various excipients.
MUPPARAJU, SUNDEEP, SURYADEVARA, VIDYADHARA, DOPPALAPUDI, SANDEEP   +2 more
core  

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review

Viruses, 2023
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on
Kaiming Tao, Soo-Yon Rhee, Carolyn Chu, A. Avalos, A. K. Ahluwalia, Ravindra K. Gupta, Michael I. Jordan, R. Shafer   +7 more
semanticscholar   +1 more source